Tetra Radar · FDA Approvals · Decision date

relacorilant: FDA decision date

Corcept Therapeutics Incorporated (CORT) · 17 December 2026

Relacorilant for patients with Cushing’s syndrome – Resubmitted New Drug Application Prescription Drug User Fee Act (PDUFA) date of December 17, 2026.

Source: 8-K of 3 November 2026

The decision is pending.

Corcept Therapeutics Incorporated on Tetra Radar

A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.

Get the Dispatch free.